Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CCR3 | P51677 | 3/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28994557 | 0.91 | PRMT6 (0.60) | CCR3 | |
| SCHEMBL7246333 | 0.86 | CARM1 (0.60) | HTR7CCR3KDM4EALDH1A1MEN1 | |
| SCHEMBL7249732 | 0.85 | HTR7 (0.70) | HTR7KCNH2CCR3SIGMAR1TMEM97 | |
| SCHEMBL5888792 | 0.84 | HTR7 (0.68) | HTR7KCNH2CCR3SIGMAR1 | |
| SCHEMBL27500330 | 0.84 | CARM1 (0.52) | — | |
| SCHEMBL7247107 | 0.84 | KCNH2 (0.61) | HTR7KCNH2CCR3SIGMAR1KDM4E | |
| Bromide SCHEMBL7247104 | 0.83 | KCNH2 (0.60) | HTR7KCNH2CCR3SIGMAR1KDM4E | |
| SCHEMBL7251474 | 0.82 | HTR7 (0.63) | HTR7KCNH2CCR3SIGMAR1 | |
| SCHEMBL4924023 | 0.81 | LMNA (0.59) | CCR3SIGMAR1 | |
| SCHEMBL7012490 | 0.81 | CCR3 (0.67) | HTR7KCNH2CCR3SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019016-B2 | Therapy of sensorineural hearing loss in a mammal by administering NR2B subunit selective N-methyl-D-aspartate (NMDA) NR2B subtype receptor antagonist | PFIZER INC (US) | 2006-03-28 | — | — | US | disclosed |
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2003-07-31 | — | — | US | disclosed |
| US-6534522-B2 | E.g.,N-((4-amino-3-nitrophenoxy)ethyl)-1,2,3,4-tetrahydro -isoquinoline; stroke; antiischemic agents; CNS trauma, hyperglycemic agents; surgery; neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis | WARNER-LAMBERT COMPANY | 2003-03-18 | — | — | US | disclosed |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | BIGGE CHRISTOPHER F (US) | 2001-12-13 | — | — | US | disclosed |
| US-6218404-B1 | THERAPY AND PROPHYLAXIS OF NEURONAL LOSS ASSOCIATED WITH STROKE, ISCHEMIA, CNS TRAUMA, HYPOGLYCEMIA AND SURGERY, NEURO-DEGENERATIVE DISEASES INCLUDING ALZHEIMER'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS, HUNTINGTON'S DISEASE | WARNER-LAMBERT CO. | 2001-04-17 | — | — | US | disclosed |
| WO-1997023458-A1 | SUBTYPE-SELECTIVE NMDA RECEPTOR LIGANDS AND THE USE THEREOF | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144319-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | HTR7 143/4885KCNH2 615/4885CCR3 3050/4885 |
| US-20010051633-A1 | Subtype-selective NMDA receptor ligands and the use thereof | OPRK1, OPRD1, OPRL1 | HTR7 143/4885KCNH2 615/4885CCR3 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.